Literature DB >> 24091907

Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis.

Brindusa Truta1, Dan X Li, Uma Mahadevan, Elena R Fisher, Yunn-Y Chen, Kim Grace, Fernando Velayos, Jonathan P Terdiman.   

Abstract

BACKGROUND AND AIMS: One of the causes of pouch failure after ileal pouch anal anastomosis (IPAA) for ulcerative colitis (UC) is the development of de novo Crohn's disease (CD). Our aim was to clearly define factors associated with post-IPAA CD.
METHODS: We conducted a cross-sectional study to compare demographic, clinical, and serological characteristics of patients with and without post-IPAA CD. All subjects underwent testing for anti-neutrophil cytoplasm antibodies, anti-Saccaromyces cerevisiae antibodies, anti-outer membrane porin C antibodies, and anti-CBir1 flagellin (anti-CBir1). A multivariable model assessed factors associated with post-IPAA CD.
RESULTS: Thirty-nine subjects were enrolled in the study: 20 cases and 19 controls. Patients who developed post-IPAA CD were significantly younger (median 22 ± 9.9 vs. 30 ± 11.3, p = .027) at the time of UC diagnosis and exhibited more extraintestinal manifestations compared to controls (p = .023). No significant difference between the groups was found with respect to family history, smoking, duration of illness prior to colectomy, time to the onset of pouchitis, preoperative treatment, and indication for surgery. However, the post-operative serologic profile differed significantly with far more cases having elevated anti-CBir1 titers (p = .016, OR 8.81), the latter being the only independent predictor in the combined model.
CONCLUSIONS: Patients with Crohn's disease of the pouch were more likely to have elevated CBir1 antibodies titers than those with simple pouchitis and healthy pouches. The stability of the CBir1 antibodies (pre- and post-colectomy) must be further assessed to establish its value as an independent predictor for development of post-IPAA CD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24091907     DOI: 10.1007/s10620-013-2866-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  The correlation between quality of life and functional outcome in ulcerative colitis patients after proctocolectomy ileal pouch anal anastomosis.

Authors:  E Carmon; A Keidar; A Ravid; G Goldman; M Rabau
Journal:  Colorectal Dis       Date:  2003-05       Impact factor: 3.788

2.  The effect of Crohn's disease on outcomes after restorative proctocolectomy.

Authors:  George E Reese; Richard E Lovegrove; Henry S Tilney; Takayuki Yamamoto; Alexander G Heriot; Victor W Fazio; Paris P Tekkis
Journal:  Dis Colon Rectum       Date:  2007-02       Impact factor: 4.585

Review 3.  IBD serological panels: facts and perspectives.

Authors:  Laurent Peyrin-Biroulet; Annie Standaert-Vitse; Julien Branche; Mathias Chamaillard
Journal:  Inflamm Bowel Dis       Date:  2007-12       Impact factor: 5.325

4.  Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup.

Authors:  E A Vasiliauskas; S E Plevy; C J Landers; S W Binder; D M Ferguson; H Yang; J I Rotter; A Vidrich; S R Targan
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

5.  Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients.

Authors:  Willem E Hueting; Erik Buskens; Ingeborg van der Tweel; Hein G Gooszen; Cees J H M van Laarhoven
Journal:  Dig Surg       Date:  2005-04-14       Impact factor: 2.588

6.  Proctocolectomy without ileostomy for ulcerative colitis.

Authors:  A G Parks; R J Nicholls
Journal:  Br Med J       Date:  1978-07-08

7.  Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

Authors:  Stephan R Targan; Carol J Landers; Huiying Yang; Michael J Lodes; Yingzi Cong; Konstantinos A Papadakis; Eric Vasiliauskas; Charles O Elson; Robert M Hershberg
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

8.  Outcome of ileal pouch after secondary diagnosis of Crohn's disease.

Authors:  V Peyrègne; Y Francois; F N Gilly; J L Descos; B Flourie; J Vignal
Journal:  Int J Colorectal Dis       Date:  2000-02       Impact factor: 2.571

9.  Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis.

Authors:  Conor P Delaney; Feza H Remzi; Terry Gramlich; Babak Dadvand; Victor W Fazio
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

10.  Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis.

Authors:  Gil Y Melmed; Phillip R Fleshner; Ovunc Bardakcioglu; Andrew Ippoliti; Eric A Vasiliauskas; Konstantinos A Papadakis; Marla Dubinsky; Carol Landers; Jerome I Rotter; Stephan R Targan
Journal:  Dis Colon Rectum       Date:  2007-12-18       Impact factor: 4.585

View more
  4 in total

1.  Effects of age at disease onset and at treatment on serology in inflammatory bowel diseases.

Authors:  Gianluca Pellino
Journal:  Dig Dis Sci       Date:  2014-11-04       Impact factor: 3.199

2.  Serological, genetic and clinical associations with increased health-care resource utilization in inflammatory bowel disease.

Authors:  Phillip Gu; Anshika Kapur; Dalin Li; Talin Haritunians; Eric Vasiliauskas; David Q Shih; Stephan R Targan; Brennan Mr Spiegel; Dermot Pb Mcgovern; Jeanne T Black; Gil Y Melmed
Journal:  J Dig Dis       Date:  2018-01       Impact factor: 2.325

3.  When Not to Pouch: Important Considerations for Patient Selection for Ileal Pouch-Anal Anastomosis.

Authors:  Shannon Chang; Bo Shen; Feza Remzi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-08

4.  Patchy colitis, and young age at diagnosis and at the time of surgery predict subsequent development of Crohn's disease after ileal pouch-anal anastomosis surgery for ulcerative colitis.

Authors:  Alexandra G Abel; Alvin Chung; Eldho Paul; Peter R Gibson; Miles P Sparrow
Journal:  JGH Open       Date:  2018-01-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.